Summary The INK4A gene which codes for the cyclin-dependent kinase (CDK) inhibitor INK4A or p16 underlies susceptibility to melanoma in some families. Germline mutations in the gene that codes for the target protein of p16, CDK4, underlie susceptibility in very rare families. We report mutation screening of the INK4A and CDK4 genes in 42 UK families. A total of nine families were identified with INK4A mutations and none with CDK4 exon 2 mutations. These mutations were in 8/22 (35%) families with three or more cases of melanoma and 1/20 (5%) families with only two cases. In one of these nine families a novel single base pair substitution was identified, Gly67Arg. In an attempt to identify another melanoma susceptibility gene, a member of the INK4 family, the p19 INK4D gene has been studied. The p19 gene was sequenced in DNA from the 42 UK families and six additional US families. No mutations were identified.
Rare families exist in which there appears to be a predisposition to cutaneous melanoma (Clark et al, 1978; Newton, 1994) . In some families, there is an apparent susceptibility to other tumours, particularly to pancreatic (Lynch and Fusaro, 1991) and other gastrointestinal cancers ), but in most families the susceptibility appears to be to melanoma alone. Early linkage data suggestive of linkage to chromosome 1 (Bale et al, 1989; Goldstein et al, 1993) have not been substantiated (Gruis et al, 1990; Nancarrow et al, 1992) , but strong evidence of linkage to chromosome 9 (Cannon-Albright et al, 1992; Nancarrow et al, 1993) was quickly followed by the identification of germline mutations in the INK4A (CDKN2) gene (on chromosome 9p) which codes for the p16 protein, in melanoma families (Hussussian et al, 1994; Kamb et al, 1994) . Mutations in this gene have been identified in the germline of families world-wide (Dracopoli and Fountain, 1996) , mutations that co-segregate with cases and for which abnormal CDK4 binding has been demonstrated (Harland et al, 1997) . The proportion of families with mutations, however, remains moderate, at around 40% of families with three or more cases overall. In our initial UK series, five of 12 families of this type, and one of 12 families with two cases of melanoma had identifiable mutations in the INK4A gene (Harland et al, 1997) .
There is some evidence for linkage to chromosome 9 even in families without identifiable INK4A mutations (Hussussian et al, 1994; Liu et al, 1997) so that there may be additional mutations yet to be identified in the promoter region of the gene, or in other linked genes. No significant contribution has been identified from two candidate genes in this region, coding for the protein p15 and p14ARF (Fitzgerald et al, 1996) . There are, however, haplotype data to suggest that there are likely to be other melanoma susceptibility genes elsewhere MacGeoch et al, 1994) . Zuo et al (1996) have identified one such gene. They reported mutations in the gene that codes for the target protein of p16, CDK4. Three families have now been reported world-wide in which germline CDK4 mutations have been detected in melanoma families (Zuo et al, 1996; Bressac-de-Paillerets et al, 1997) . In these families, single base pair substitutions were detected at the same point in the p16-binding domain, residue 24 and, more recently, mutations have been detected in a second domain also important in binding to cyclin D1 (Coleman et al, 1997) , strengthening considerably the significance of the p16-CDK4-RB pathway in melanoma carcinogenesis. Several groups have now looked at their melanoma families without identifiable INK4A mutations and have failed to identify additional CDK4 mutations. It is clear, therefore, that CDK4 mutations are rare (Harland et al, 1997) and that there are other melanoma susceptibility genes still to identify.
p16 is a member of a family of CDK inhibitors, the INK4 family. The two cyclin D-dependent CDKs, CDK4 and CDK6, induce phosphorylation of the retinoblastoma protein (RB1), thereby releasing RB1 from its growth inhibitory functions. In turn, the proteins from the INK4 family inhibit this process and act as brakes to phase G1 of the cell cycle (Hirama and Koeffler, 1995; Sherr and Roberts, 1995; Sherr, 1996) . There are at least four members of the family, p16INK4A, p15INK4B, p18INK4C and p19INK4D (to be distinguished from p14ARF). The expression of the INK4 genes shows tissue specificity suggesting lack of redundancy (Sherr, 1996) . The polypeptides are composed of 4-5 ankyrin repeats, and mutagenesis studies have suggested that mutations are likely to affect function only if they occur in the region coding for these ankyrin repeats . There is a little information which suggests that the INK4 family members may have a role in cellular differentiation via effects of the CDKs on phosphorylation of substrates other than RB; for example, p18 and p19 which are widely expressed during embryogenesis (Zindy et al, 1997) .
All members of the family bind to CDK4 and 6 (Hirai et al, 1995; Guan et al, 1996) . They have a moderate degree of homology. p19INK4D, for example, has 48% amino acid homology with p16INK4A. All members of the family compete with cyclin D1 for its binding site on CDKs (Guan et al, 1996) . The presence of each member of the family in phase G1 will induce G1 arrest, so that at a cellular level at least all members of the family are potential tumour suppresser genes. We chose p19 INK4D as a candidate gene because of its chromosomal location at 19p13.2, a reported site of repeated translocation in melanoma tumours (Parmiter et al, 1986) .
MATERIALS AND METHODS
DNA from 42 UK families at increased risk of melanoma was screened for germline mutations. The families have been recruited in the period since 1989 in England and Wales. Ethical Committee approval for this study was obtained from all institutions involved. Twenty-two of these families have been previously described (Harland et al, 1997) . Wherever possible, DNA from two cases from each family was screened. Six additional US families were screened for INK4D mutations. These families were selected because they had sarcoma and/or haematological malignancies in addition to melanoma. Three of these families have been previously described Liu et al, 1997) .
DNA extraction and PCR
DNA extraction from peripheral blood, and the polymerase chain reaction (PCR) amplification of the three coding exons of INK4A, and exon 2 of CDK4, was carried out as described previously (Harland et al, 1997) .
Analysis of p19 INK4D
Previously, only the cDNA sequence has been available for p19 INK4D (GenBank accession numbers U40343, U20498 and U49399). Studies using primers designed from this sequence have been able to cover, at best, 85% of the coding sequence of INK4D (Shiohara et al, 1996; Miller et al, 1997) . In order to examine the terminal amino acids in each of the two exons of INK4D, and also the splice donor and acceptor sites, it was important to determine the intronic sequence of INK4D, so that intronic primers flanking the two coding exons could be designed. Primers flanking the cDNA sequence were designed from the available sequence for the 3′ and 5′ non-coding regions (Guan et al, 1996) (GenBank accession number U40343). Long-range PCR across the two exons and the intron, in genomic DNA samples, produced a PCR product approximately 1100 bp longer than would be predicted from the cDNA sequence. Sequencing through the coding regions and into the intron has enabled us to determine the complete intronic sequence of INK4D, 1091 bases in total. This sequence, which has been submitted to GenBank (accession number AF061327), has enabled us to design primers flanking the two exons of p19, and so allowed us to investigate the complete coding region of p19 INK4D in our families.
Long-range PCR of p19 INK4D
Primers were based on the p19 INK4D cDNA sequence (GenBank accession number U40343) ( Table 1) . A total of 100 µl long-range PCR reactions were carried out using 250 ng genomic DNA, 0.2 mM dNTPs, 50 µM each primer, 10% dimethyl sulphoxide (DMSO), and 5 units Deep Vent DNA polymerase (New England Biolabs), in the reaction buffer provided by the supplier. Thermal cycling conditions were as follows: an initial denaturation at 94°C for 5 min; followed by 35 cycles of denaturing at 94°C (30), annealing at 55°C (30), and extension at 72°C (6′), with a final 10-min extension at 72°C. PCR fragments were isolated by agarose gel electrophoresis and purified prior to sequencing using the QIAquick Gel Extraction Kit (Quiagen). Sequencing of the intronic region was performed as described below, using forward and reverse primers designed from the known cDNA sequence, and also primers designed from generated intronic sequence (Table 1) . PCR amplification for the screening of the two exons of p19 INK4D, was carried out as described previously for INK4A and CDK4 (Harland et al, 1997) , the primers used are shown in Table 1 .
Sequencing
Sequencing reactions were carried out using the ABI PRISM BigDye Terminator Cycle Sequencing Kit (Perkin-Elmer) and the products were analysed on an ABI 377 DNA sequencer. DNA sequencing was performed in both directions, initiated from the forward and reverse primers used in the initial PCR amplification of each exon. In kindreds where sequence variation was found in one or both of the initial samples selected for investigation, all members of that family, for whom DNA was available, were sequenced for the putative mutation identified in the initial samples, in order to study the segregation of the mutation with melanoma. Table 2 shows the characteristics of the families screened. Fortytwo UK families were mutation tested (Table 3) . Partial testing was reported in 22 of these families previously (Harland et al, 1997) . Six additional US families were screened for INK4D mutations in whom significant INK4A and CDK4 mutations had previously been excluded (Hussussian et al, 1994) . In one of these families, Asn71Ser was identified. This mutation has not yet been shown to have functional implications (Ranada et al, 1995) . In total, 26 families with three or more cases, and 22 with only two cases of melanoma were screened. In nine of the 22 families with two cases of melanoma, one of those cases had proven multiple primary tumours, as additional evidence for an underlying genetic susceptibility to melanoma. The three UK families not previously reported with germline mutations had Arg24Pro (in common with another UK family and several others world-wide), Met53Ile (again in common with a second UK family and others world-wide) and a novel single base pair substitution Gly67Arg (Figure 1) .
RESULTS
A previously reported polymorphism in exon 1 of INK4D, was detected in codon 30 (Miller et al, 1997) in cases from five families with three or more cases of melanoma and one family with two cases only. No mutations were identified in either CDK4 exon 2 or the INK4D genes.
DISCUSSION
INK4A (CDKN2) clearly underlies susceptibility to melanoma in a significant proportion of melanoma-prone families, and germline mutations in the CDK4 gene underlie susceptibility in a small minority of families. We report three new families with germline mutations. Two of these have been widely reported in other centres, and in all families the mutations co-segregate with the tumours. Furthermore, functional assays have shown these mutations to be significant (Harland et al, 1997) . The novel mutation Gly67Arg has not, to our knowledge, been reported before, but it occurs at a site predicted by the ankyrin structure of the p16 protein, to be critical to function. A similar, single base pair substitution at the same codon has been detected in an Australian pedigree (Mann et al, 1997) .
In this series of 42 UK families recruited since 1989, 36% of families with three or more cases and 5% of families with only two cases had identifiable INK4A mutations. The prevalence of germline INK4A mutations in the larger families is consistent with that reported world-wide. Some authors have suggested that approximately 25% of families with two or more cases in Australia, Europe and the USA have identifiable mutations, and in a population-based study in Sweden by Platz et al the frequency of these mutations was estimated to be even lower (Platz et al, 1997) . G  MEL24  3  No  88delG  MEL28  3  No  MEL30  3  No  MEL35  3  No  90C/G  MEL44  3  Yes  90C/G  MEL50  3  No  90C/G  MEL53  3  Yes  90C/G  NIH 3  3  Yes  Asn71Ser  NIH 4 3 No
Polymorphisms are indicated in italics. The protein produced by mutation Asn71Ser has been normal in vitro testing.
The reported studies are difficult to compare, as noted by Goldstein and Tucker (1997) , because different groups have been variably stringent in their selection criteria. Some stipulate that the number of cases reported should be in first-degree relatives, others do not. Furthermore, groups appear to vary in how rigorously they sought mutations. In this study, there appears to be a clear difference in the likelihood of identifying germline INK4A mutations in families of different sizes. Mutations were significantly more likely in families with larger numbers of cases (Table 4 ). This might imply that the families with larger numbers of cases are less likely to represent clustering of cases by chance alone, or that they carry more penetrant genes. Overall, in the families with three or more cases, 64% did not have identifiable INK4A mutations, nor did they have the rarer CDK4 exon 2 mutations. There is some evidence from other groups that some families without detectable INK4A mutations still have evidence of linkage to chromosome 9 (Walker et al, 1995) and it may be that, in these families, there are still to be found mutations in intronic sequences or the promoter that have an effect on p16 transcription.
There is some evidence for linkage to other chromosomes (Bale et al, 1989; Walker et al, 1994) and we have previously reported suggestive haplotype data (MacGeoch et al, 1994) so that it also seems likely that there are other high penetrance melanoma susceptibility genes to be identified. We have taken a candidate gene approach to the identification of such genes. It would seem that the p16/RB1 pathway is of critical importance in melanoma carcinogenesis and therefore we chose to look at another member of the INK4 family, p19 INK4D.
The four members of the INK4 family appear to function in a similar way in terms of binding to CDK4/6 and inducing G1 arrest. (Fitzgerald et al, 1996; Liu et al, 1997) . INK4D is the most recently described member of the INK4 family and the gene is on chromosome 19 (19p13) . Structural chromosome breakpoints are reported in around 4% of short-term melanoma cultures on 19p (Nelson et al, 1996) . The chromosomal location of INK4D is, however, of most interest because of a report by Parmiter et al (1986) of a translocation involving chromosome 19 at 19p13 in three cases of melanoma. In only one line, an ovarian cancer cell line SKOV3, was there a single base pair deletion in exon 1 of INK4D (Gemma et al, 1996) . In tumour samples, abnormalities have rarely been reported (Shiohara et al, 1996; Miller et al, 1997) . These studies in cell lines and tumour samples suggest a possible role for INK4D in some specific tumour types but suggest that INK4D is not a tumour suppresser gene of such fundamental importance as INK4A. In summary, we have not found any significant INK4D mutations in the germline of 48 families with a susceptibility to melanoma. Its similar function to that of INK4A and its chromosomal location at a site of translocations in melanoma patients, made it a candidate gene for genetic susceptibility to melanoma. To date we have no evidence for such a role, but it might reasonably be argued that if p19 does underlie susceptibility in some families, these families are likely to be rare and screening of samples from other continents should also be carried out.
